Markets BTIG cuts Obalon Therapeutics PT to $7 from $13 BTIG lowered its price target for Obalon Therapeutics (NASDAQ:OBLN) to $7 from $13 after the company reported in-line fourth quarter results and guidance for 2018. The stock finished at $4.01 on March 5. Obalon is... March 6, 2018